Details

Mortality, seasonal variation, and susceptibility to acute exacerbation of COPD in the pandemic year : a nationwide population study
ID Šarc, Irena (Author), ID Lotrič Dolinar, Aleša (Author), ID Morgan, Tina (Author), ID Sambt, Jože (Author), ID Ziherl, Kristina (Author), ID Gavrić, Dalibor (Author), ID Šelb, Julij (Author), ID Rozman, Aleš (Author), ID Došenović Bonča, Petra (Author)

.pdfPDF - Presentation file, Download (1,43 MB)
MD5: 80EFD7115F7818654C8C178E9A8E632B
URLURL - Source URL, Visit https://journals.sagepub.com/doi/10.1177/17534666221081047 This link opens in a new window

Abstract
Background: Previous studies have suggested that the coronavirus disease 2019 (COVID-19) pandemic was associated with a decreased rate of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Data on how the COVID-19 pandemic has influenced mortality, seasonality of, and susceptibility to AECOPD in the chronic obstructive pulmonary disease (COPD) population is scarce. Methods: We conducted a national population-based retrospective study using data from the Health Insurance Institute of Slovenia from 2015 to February 2021, with 2015–2019 as the reference. We extracted patient and healthcare data for AECOPD, dividing AECOPD into severe, resulting in hospitalisation, and moderate, requiring outpatient care. The national COPD population was generated based on dispensed prescriptions of inhalation therapies, and moderate AECOPD events were analysed based on dispensed AECOPD medications. We extracted data on all-cause and non-COVID mortality. Results: The numbers of severe and moderate AECOPD were reduced by 48% and 34%, respectively, in 2020. In the pandemic year, the seasonality of AECOPD was reversed, with a 1.5-fold higher number of severe AECOPD in summer compared to winter. The proportion of frequent exacerbators (2 AECOPD hospitalisations per year) was reduced by 9% in 2020, with a 30% reduction in repeated severe AECOPD in frequent exacerbators and a 34% reduction in persistent frequent exacerbators (2 AECOPD hospitalisations per year for 2 consecutive years) from 2019. The risk of two or more moderate AECOPD decreased by 43% in 2020. In the multivariate model, pandemic year follow-up was the only independent factor associated with a decreased risk for severe AECOPD (hazard ratio [HR]: 0.71; 95% confidence interval [CI]: 0.61–0.84; p < 0.0001). In 2020, non-COVID mortality decreased (−15%) and no excessive mortality was observed in the COPD population. Conclusion: In the pandemic year, we found decreased susceptibility to AECOPD across severity spectrum of COPD, reversed seasonal distribution of severe AECOPD and decreased non-COVID mortality in the COPD population.

Language:English
Keywords:exacerbation, acute exacerbation, seasonal variations, population study, COPD, COVID-19 pandemic, seasonality
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
EF - School of Economics and Business
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:Str. 1-15
Numbering:Vol. 16
PID:20.500.12556/RUL-135702 This link opens in a new window
UDC:616.2
ISSN on article:1753-4658
DOI:10.1177/17534666221081047 This link opens in a new window
COBISS.SI-ID:100243459 This link opens in a new window
Publication date in RUL:29.03.2022
Views:1761
Downloads:167
Metadata:XML DC-XML DC-RDF
:
ŠARC, Irena, LOTRIČ DOLINAR, Aleša, MORGAN, Tina, SAMBT, Jože, ZIHERL, Kristina, GAVRIĆ, Dalibor, ŠELB, Julij, ROZMAN, Aleš and DOŠENOVIĆ BONČA, Petra, 2022, Mortality, seasonal variation, and susceptibility to acute exacerbation of COPD in the pandemic year : a nationwide population study. Therapeutic advances in respiratory disease [online]. 2022. Vol. 16, p. 1–15. [Accessed 31 March 2025]. DOI 10.1177/17534666221081047. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=135702
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Therapeutic advances in respiratory disease
Shortened title:Ther. adv. respir. dis.
Publisher:Sage
ISSN:1753-4658
COBISS.SI-ID:514982169 This link opens in a new window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:07.03.2022

Secondary language

Language:Slovenian
Keywords:poslabšanje, akutno poslabšanje, sezonska nihanja, populacijska raziskava

Similar documents

Similar works from RUL:
  1. Review of the treatment of advanced non-small-cell lung cancer patients with mutation in the epidermal growth factor during the years of 2010 and 2014 at the University Clinic Golnik
  2. Vpliv izražanja receptorja za inzulinu podoben rastni dejavnik 1 (IGF1R) na preživetje pri razsejanem nedrobnoceličnem raku pljuč
  3. Evaluation of possible pembrolizumab dosing regimen racionalisation in advanced non-small cell lung cancer
Similar works from other Slovenian collections:
  1. Epidermal growth factor receptor mutations and treatment of non-small-cell lung cancer
  2. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  3. Multicenter evaluation of the fully automated PCR-based Idylla EGFR Mutation Assay on formalin-fixed, paraffin-embedded Q1 tissue of human lung cancer
  4. Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA)
  5. Real-world testing practices, treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer

Back